Zoetis has announced that Simparica Trio has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the treatment of infestations caused by New World screwworm (Cochliomyia hominivorax) larvae, also known as myiasis, in dogs and puppies

The authorization provides veterinarians with an additional treatment option as New World screwworm continues to pose a threat to animals in the United States. If left untreated, infestations can result in serious injury and suffering in affected animals.

Click here to join our WhatsApp channel here

Simparica Trio is a monthly chewable tablet containing sarolaner, moxidectin and pyrantel. It is already FDA-approved for several other parasite-related indications in dogs, including protection against heartworm disease, ticks, fleas, roundworms and hookworms.

“At Zoetis, our highest priority is protecting the health and well-being of animals,” said Abhay Nayak, EVP and President, U.S. Commercial Operations at Zoetis. “The Emergency Use Authorization for Simparica Trio provides an important new tool in the fight against New World screwworm, a devastating parasite that can cause severe suffering in dogs. With this milestone, Simparica Trio helps simplify parasite protection for dogs with a single monthly chew supporting both routine control and New World screwworm response needs.”

The authorization is part of broader efforts to strengthen preparedness and response to New World screwworm across companion animals and livestock.

Pet owners are advised to consult veterinarians if they notice suspicious wounds, maggots or signs of infestation in their dogs.

Also read: Saudi Arabia’s Digital Health Sector Takes Centre Stage at Global Health Exhibition 2026